Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas.
DNA prognosis
T-cell lymphoma
haematological malignancies
prognostic factors
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
04 Jan 2024
04 Jan 2024
Historique:
revised:
14
12
2023
received:
03
10
2023
accepted:
19
12
2023
medline:
5
1
2024
pubmed:
5
1
2024
entrez:
4
1
2024
Statut:
aheadofprint
Résumé
Peripheral T-cell lymphomas (PTCLs) have a poor prognosis and, to date, there are no reliable predictive biomarkers of response. In this work we explored the prognostic impact of cell-free DNA (cfDNA) concentration in 75 newly diagnosed patients enrolled in a prospective multicenter study. Pre-treatment cfDNA was strongly associated with clinical risk factors and was identified as a superior predictor for shorter progression-free survival in multivariable analysis, outweighing canonical risk parameters. Furthermore, we identified a cfDNA value above which survival worsens. In conclusion, pre-treatment cfDNA concentration represents an easily usable predictive biomarker that is highly associated with survival of PTCL patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG22089
Organisme : Associazione Italiana Contro le Leucemie - Linfomi e Mieloma
Informations de copyright
© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood. 2014;123:2636-2644.
Piccaluga PP, Agostinelli C, Gazzola A, Mannu C, Bacci F, Sabattini E, et al. Prognostic markers in peripheral T-cell lymphoma. Curr Hematol Malig Rep. 2010;5:222-228. https://doi.org/10.1007/s11899-010-0062-x
Yan YY, Guo QR, Wang FH, Adhikari R, Zhu ZY, Zhang HY, et al. Cell-free DNA: Hope and potential application in cancer. Front Cell Dev Biol. 2021;9:639233.
Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989;46:318-322. Available from: http://karger.com/ocl/article-pdf/46/5/318/3273072/000226740.pdf
Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer - a survey. Biochim Biophys Acta Rev Cancer. 2007;1775:181-232. https://doi.org/10.1016/j.bbcan.2006.10.001
Wu J, Tang W, Huang L, Hou N, Wu J, Cheng X, et al. The analysis of cell-free DNA concentrations and integrity in serum of initial and treated of lymphoma patients. Clin Biochem. 2019;63:59-65.
Schroers-Martin JG, Kurtz DM, Soo J, Jin MC, Scherer F, Craig AF, et al. Determinants of circulating tumor DNA levels across lymphoma histologic subtypes. Blood. 2017;130:4018.
Hur JY, Kim YJ, Yoon SE, Son DS, Park WY, Kim SJ, et al. Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas. Ann Hematol. 2020;99:1293-1302.
Andrade-Campos MM, Salar A, Sanchez-Gonzalez B, Fernández-Rodríguez C, Gimeno E, Ruiz L, et al. Assessment of cell-free DNA (cfDNA) in 221 patients with lymphoproliferative malignancies at diagnosis and during follow-up. Blood. 2019;134:492.
Chiappella A, Dodero A, Evangelista A, Re A, Orsucci L, Usai SV, et al. Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study. Leukemia. 2023;37:433-440. https://doi.org/10.1038/s41375-022-01780-1
Biancon G, Gimondi S, Vendramin A, Carniti C, Corradini P. Noninvasive molecular monitoring in multiple myeloma patients using cell-free tumor DNA: a pilot study. J Mol Diagn. 2018;20:859-870.